

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10582712
	Filing Date		2007-02-02
	First Named Inventor	EILAT	
	Art Unit	1616	
	Examiner Name	Mina Haghighatian	
Attorney Docket Number		EILAT=3	

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS								
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² _i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10582712
Filing Date	2007-02-02
First Named Inventor	EILAT
Art Unit	1616
Examiner Name	Mina Haghighatian
Attorney Docket Number	EILAT=3

1	Ardizzone et al., "Mesalazine foam (Salofalk foam) in the treatment of active distal ulcerative colitis. A comparative trial vs. Salofalk enema. The SAF-3 study group" Ital J. Gastroenterol Hepatol 31:677-84 (1999) (Abstract)	<input type="checkbox"/>
2	Borelli et al., "Crema or foam in perianal skin care: towards the ideal vehicle for urea used against dry skin, Int. J. Cosmet Sci 33:37-43 (2011)	<input type="checkbox"/>
3	Cortot et al., "Mesalazine foam enema vs. mesalazine liquid enema in active left-sided ulcerative colitis" Am J. Gastroenterol 103(12):3106-14 (2008)	<input type="checkbox"/>
4	Farup et al., "Mesalazine suppositories versus hydrocortisone foam in patients with distal ulcerative colitis. A comparison of the efficacy and practicality of two topical treatment regimens." Scand J. Gastroenterol 30(2):164-170 (1995)	<input type="checkbox"/>
5	Franz "Bioavailability of clobetasol propionate in different vehicles." Skin Pharmacol Appl Skin Physiol, 16(4):212-216 (2003) (Abstract)	<input type="checkbox"/>
6	Gross et al., "Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis" Aliment Pharmacol Ther 23:303-312 (2006)	<input type="checkbox"/>
7	Lucidarme et al., "Efficacy and tolerance of mesalazine suppositories vs. hydrocortisone foam in proctitis" Aliment Pharmacol Ther 11(2):335-340 (1997) (Abstract)	<input type="checkbox"/>
8	Ngo et al., "[5-aminosalicylic acid enema (Pentasa) versus hydrocortisone acetate foam (Proctocort) for the treatment of outbreaks of proctitis and cryptogenic proctosigmoiditis. A comparative randomized multicentered trial]" Gastroenterol Clin Biol 16(6-7):558-563 (1992) (Abstract)	<input type="checkbox"/>
9	Ruddell et al., "Treatment of distal ulcerative colitis (proctosigmoiditis) in relapse: comparison of hydrocortisone enemas and rectal hydrocortisone foam" Gut, 21:885-889 (1980)	<input type="checkbox"/>
10	Somerville et al., "Effect of treatment on symptoms and quality of life in patients with ulcerative colitis: comparative trial of hydrocortisone acetate foam and prednisolone 21-phosphate enemas" British Medical Journal 291:866 (1985)	<input type="checkbox"/>
11	Tarpila et al., "Budesonide Enema in active hemorrhagic proctitis — a controlled trial against hydrocortisone foam enema" Aliment Pharmacol. Ther 8(6):591-595 (1994) (Abstract)	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10582712
Filing Date	2007-02-02
First Named Inventor	EILAT
Art Unit	1616
Examiner Name	Mina Haghighatian
Attorney Docket Number	EILAT=3

12	Woodford et al., "Bioavailability and activity of topical corticosteroids from a novel drug delivery system, the aerosol quick-break foam" J. Pharm Sci 66(1):99-103 (1977) (Abstract)	<input type="checkbox"/>
----	--	--------------------------

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.